221 related articles for article (PubMed ID: 19707272)
1. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.
Fintini D; Brufani C; Cappa M
Ther Clin Risk Manag; 2009 Jun; 5(3):553-9. PubMed ID: 19707272
[TBL] [Abstract][Full Text] [Related]
2. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
Kemp SF
BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
[TBL] [Abstract][Full Text] [Related]
4. Mecasermin.
Keating GM
BioDrugs; 2008; 22(3):177-88. PubMed ID: 18481900
[TBL] [Abstract][Full Text] [Related]
5. Mecasermin (recombinant human insulin-like growth factor I).
Rosenbloom AL
Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
[TBL] [Abstract][Full Text] [Related]
6. Significance of Direct Confirmation of Growth Hormone Insensitivity for the Diagnosis of Primary IGF-I Deficiency.
Smyczyńska J; Smyczyńska U; Hilczer M; Stawerska R; Lewiński A
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31963242
[TBL] [Abstract][Full Text] [Related]
7. Recombinant insulin-like growth factor-1 as a therapy for IGF-1 deficiency in renal failure.
Clark RG
Pediatr Nephrol; 2005 Mar; 20(3):290-4. PubMed ID: 15682316
[TBL] [Abstract][Full Text] [Related]
8. Managing the child with severe primary insulin-like growth factor-1 deficiency (IGFD): IGFD diagnosis and management.
Cohen J; Blethen S; Kuntze J; Smith SL; Lomax KG; Mathew PM
Drugs R D; 2014 Mar; 14(1):25-9. PubMed ID: 24639006
[TBL] [Abstract][Full Text] [Related]
9. Cardiac examination in children with Laron syndrome undergoing mecasermin therapy.
Erol N; Yıldız M; Güven A; Yıldırım A
J Pediatr Endocrinol Metab; 2018 Jun; 31(6):675-679. PubMed ID: 29750649
[TBL] [Abstract][Full Text] [Related]
10. Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry.
Bang P; Polak M; Bossowski A; Maghnie M; Argente J; Ramon-Krauel M; Sert C; Perrot V; Mazain S; Woelfle J
J Clin Endocrinol Metab; 2023 Dec; 109(1):46-56. PubMed ID: 37579214
[TBL] [Abstract][Full Text] [Related]
11. Spectrum of insulin-like growth factor deficiency.
Wit JM; Oostdijk W; Losekoot M
Endocr Dev; 2012; 23():30-41. PubMed ID: 23182818
[TBL] [Abstract][Full Text] [Related]
12. The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome).
Cotterill AM; Camacho-Hübner C; Holly JM; Savage MO
Clin Endocrinol (Oxf); 1993 Jul; 39(1):119-22. PubMed ID: 7688671
[TBL] [Abstract][Full Text] [Related]
13. A half-century of studies of growth hormone insensitivity/Laron syndrome: A historical perspective.
Rosenbloom AL
Growth Horm IGF Res; 2016 Jun; 28():46-50. PubMed ID: 26276451
[TBL] [Abstract][Full Text] [Related]
14. Investigational agents for the treatment of growth hormone-insensitivity syndrome.
Kemp SF; Thrailkill KM
Expert Opin Investig Drugs; 2006 Apr; 15(4):409-15. PubMed ID: 16548790
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment.
Carel JC; Chaussain JL; Chatelain P; Savage MO
Diabetes Metab; 1996 Jul; 22(4):251-6. PubMed ID: 8767171
[TBL] [Abstract][Full Text] [Related]
16. The IGF system: new developments relevant to pediatric practice.
Rosenfeld RG
Endocr Dev; 2005; 9():1-10. PubMed ID: 15879683
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor binding protein-3 generation: an index of growth hormone insensitivity.
Thalange NK; Price DA; Gill MS; Whatmore AJ; Addison GM; Clayton PE
Pediatr Res; 1996 May; 39(5):849-55. PubMed ID: 8726240
[TBL] [Abstract][Full Text] [Related]
18. Genetic defects of the growth-hormone-IGF axis associated with growth hormone insensitivity.
Woods K
Endocr Dev; 2007; 11():6-15. PubMed ID: 17986822
[TBL] [Abstract][Full Text] [Related]
19. Mecasermin rinfabate.
Kemp SF
Drugs Today (Barc); 2007 Mar; 43(3):149-55. PubMed ID: 17380212
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
Laron Z
Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
